A rising demand for biologics means that biotech companies face a multitude of manufacturing challenges, but also plenty of opportunities. We spoke to Kevin Sharp, senior VP and head of sales at Samsung Biologics, to examine what is driving this demand...
The big pharma company Bristol Myers Squibb (BMS) has recruited contract manufacturing and development organization (CDMO) Samsung Biologics to manufacture a commercial antibody cancer treatment until 2030.
Last month, CDMO giant Samsung Biologics revealed it was planning to have its fifth plant operational by April 2025, five months earlier than previously anticipated.
Samsung Biologics’ upcoming fifth plant will be operational by April 2025, five months earlier than previously expected, the biotech company revealed at BIO International Convention on Monday 5.
Samsung Ventures, the global investment arm of Samsung Group, has invested an undisclosed amount in the Swiss company Araris Biotech. The deal is independent from Araris’ ongoing Series A fundraising and will be used to bankroll the development of antibody-drug...
Samsung Biologics has introduced two new platforms focused on optimized antibody production and systematic screening of molecules at an early development stage.
GreenLight Biosciences and Samsung Biologics have completed the first commercial-scale engineering run under the companies’ mRNA production partnership: ahead of a COVID-19 vaccine booster clinical trial due to start later this year.
Construction of Samsung Biologics’ Plant 4 is on schedule with operations set to start in October, the company confirmed in its Q2 results this morning.
Samsung Biologics says it is actively working to engage its suppliers to transition to net zero emissions in multiple areas and invest in renewable energy.
Korean contract development and manufacturing organization, Samsung Biologics, announced strong financial results today for Q1 of its fiscal year 2022.
Samsung Biologics flags further facility construction plans, with biologics, cell and gene therapies and next-generation vaccines to be the focus of those new sites.
Samsung Biologics will manufacture AstraZeneca’s COVID-19 long-lasting antibody combination (AZD7442) and cancer immunotherapy product from next year under an expanded partnership.
GreenLight Biosciences and CDMO Samsung Biologics have announced a partnership agreement, with Samsung Biologics to manufacture GreenLight’s messenger RNA COVID-19 vaccine candidate at commercial scale.
Samsung Biologics will add mRNA vaccine drug substance production capability to its facility in South Korea, aiming to provide end-to-end mRNA vaccine manufacturing services.
US biopharma firm, TG Therapeutics, has announced an expanded contract manufacturing deal with Samsung Biologics to support the production of its investigational anti-CD20 monoclonal antibody, ublituximab.
Samsung Biologics is aiming to become ‘a full-service biopharmaceutical company’: creating a greater global footprint for its CDMO business, continuing to advance its biosimilars business, and laying the groundwork for novel drug development.
2020 has been an eventful year: but 2021 will also require skilful navigation. Here's some of the people who are stepping up to leading roles as we head into a new year.
Samsung Biologics and AstraZeneca have announced a $330.8m long-term global supply agreement: helping AstraZeneca expand biologics manufacturing capabilities in Asia Pacific.
Samsung Biologics director outlines the difference between single-use and stainless steel systems, noting the difficulties of the former at large scales.
Samsung continues an agreement formerly signed with Glenmark to manufacture Ichnos’ mAb treatment candidate for atopic dermatitis, as the product enters Phase III clinical trials.
An executive at Samsung is issued an arrest warrant, as prosecutors in South Korea continue to look into the accounting case leading up the IPO of Samsung BioLogics.
Samsung Biologics is providing contract development services for GI Innovation’s pipeline, with the first among five molecules to initiate development immediately, says company representative.
Korean authorities continue to place pressure on the CDMO, after prosecutors raided the office of the national stock exchange regarding behaviour preceding the public listing of Samsung BioLogics.
Samsung plans to invest KRW 180 trillion into its various businesses over the next three years, including in biomanufacturing-focused Samsung BioLogics.
South Korea’s SFC has alleged that Samsung BioLogics had intentionally omitted information regarding the joint venture agreement with Biogen that created Samsung Bioepis.
The manufacturing contract is the first of what Samsung BioLogics expects to be a number of long-term partnerships at its recently completed 180,000L facility.
The world’s largest single bioproduction plant has received its first EU regulatory approval to make a monoclonal antibody, says CDMO Samsung Biologics.
The Korean CDMO says construction of its third – and largest – biomanufacturing facility is complete with the validation process expected to take a year.
Fresh from US approval of its second facility and ahead of the opening of a third, Samsung Biologics is now considering a fourth plant outside of Korea.
